Search Details

Word: phased (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

...neurons. The tricky part is that most trophic molecules are too big to move across the miniscule blood vessels in the brain, so Guilford and Amgen are working on a smaller one that can get where it needs to go. The progress so far is promising. "We're in Phase 2 human trials now," says Dr. Craig Smith, president of Guilford. "Although we don't have results yet, if the drug proves safe and extremely effective in trials, it could be on the market as early...

Author: /time Magazine | Title: The Hunt For Cures: Parkinson's Disease: Lubricating Gummed-Up Brains | 1/15/2001 | See Source »

...also created something of a microarray gold rush. Several firms--from pioneering Affymetrix to the upstart Incyte Genomics, based in Palo Alto, Calif.--help pharmaceutical companies identify drug targets found exclusively in diseased cells. Others, like Phase-1 Molecular Toxicology of Santa Fe, N.M., sell chips that test how chemicals affect gene expression, allowing pharmaceutical firms to quickly reject candidate drugs too toxic to be worth pursuing...

Author: /time Magazine | Title: The Workhorse of Genomic Medicine | 1/15/2001 | See Source »

ANNA NICOLE SMITH says she's sick of all the jokes about her. So we're not going to dwell on the fact that her lawyer is named Howard Stern, or that Smith, 33, hasn't been attending the latest phase in the Texas trial over her late nonagenarian husband's fortune because of a hand injury she suffered while exercising. Instead, we're just going to air her grievance that Playboy, which discovered her and launched her career, has exploited her troubles by putting her on the cover of its current issue, running old nude photos of her inside...

Author: /time Magazine | Title: People: Jan. 15, 2001 | 1/15/2001 | See Source »

...synthesized as experimental treatments for Alzheimer's disease. One of them, ABT-594, turned out to be remarkably similar but much less toxic. Tests on animals indicate that ABT-594 is about 50 times better than morphine in relieving both chronic and acute pain yet seems to be nonaddictive. Phase II tests on humans should be completed by the end of the year...

Author: /time Magazine | Title: Potions From Poisons | 1/15/2001 | See Source »

...vaccine against beta amyloid that Schenk and his co-workers at Elan have developed. In 1999 they administered their vaccine to mice whose brains were filled with plaques. A short time later, the plaques shrank. Currently the Elan vaccine, like the Bristol-Myers' secretase inhibitor, is in early-phase clinical trials, in which the primary objective is to test for safety as opposed to effectiveness...

Author: /time Magazine | Title: The Hunt For Cures: Alzheimer's Disease | 1/15/2001 | See Source »

Previous | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | Next